CONNECT, PARTNER & INNOVATE WITH THE BIOREGION OF CATALONIA AT BIO 2012 June 18-21, 2012 Booth 437 Boston Convention & Exhibition Center 415 Summer Street • Boston (USA)
CONNECT, PARTNER & INNOVATE WITH
THE BIOREGIONOF CATALONIAAT BIO 2012
June 18-21, 2012 Booth 437
Boston Convention & Exhibition Center 415 Summer Street • Boston (USA)
More information at:
www.biocat.cat/bio2012
With the support of:
BIOCAT, LEADING BIOTECHNOLOGY IN CATALONIABOOTH 437Biocat is the entity that coordinatesand promotes innovation in biotechnology, biomedicine and medical technology sector in Catalonia, following a strategic plan focused on:
• Consolidating Catalonia's biocluster• Promoting Business competitiveness• Fostering Internationalisation• Training and attracting talent• Generating a positive social perception of biotechnology
20 SCIENCE ANDTECHNOLOGYPARKS
481COMPANIES
10UNIVERSITIES(out of 12) offeringstudies in life sciencesand two of the 20top-ranked businessschools in the world
433RESEARCHGROUPS workingin life sciences
80RESEARCHCENTERSin life sciences
74(European ResearchCouncil) GRANTSawarded to Catalanscientists workingin life sciences,between 2007and 2011
13HOSPITALSwith noteworthyresearch activity(out of 214) and5 research institutesrecognized bythe Spanishgovernment
(71 pharmaceutical, 91 biotechnology, 106 innovative medical technology, 29 fine chemicals, 45 food, 9 bioinformatics and the rest provide support services or are linked to the sector in some way)
Source: Biocat Report 2011 and web Directory
ERC
BIOREGIONOF CATALONIA PAVILION
VISIT OUR PAVILION AND MEET THE KEY PLAYERS OF THE CATALAN BIOTECHNOLOGY AT BIO:
72 COMPANIES ANDSCIENTIFIC INSTITUTIONS MORE THAN 100 DELEGATES
MORE THAN 60% OF THESPANISH REPRESENTATION
FLOORPLAN FOR 2012 BIO
ENTRANCE ENTRANCE
BUSINESS FORUM
PARTNERINGDESK
BOOTH 437M
ASSA
CHUS
ETTS
ONTA
RIO
QUEB
EC
CAN
ADA
BIOMARYLAND
GERMANY ITALY
SPAINPAVILION
PEN
NSY
LVAN
IABI
O
ENTR
ANCE
BIOBASQUE
SPAIN
CATALONIA
ANDALUCIABIOREGION
FRAN
CE
GEORGIA
ENTR
ANCE
437-31 AB-BIOTICS437-47 AB-THERAPEUTICS437-42 ALTHIA437-38 ANAXOMICS437-33 AROMICS437-45 ARCHIVEL437-37 BCN PEPTIDES437-34 BIOCHEMIZE437-28 BIONURE 437-23 GP PHARM437-51 GRIFOLS ENGINEERING437-54 HEXASCREEN CULTURE TECHNOLOGIES437-41 IMMUNNOVATIVE DEVELOPMENTS437-50 INTELLIGENT PHARMA437-52 JANUS DEVELOPMENTS437-36 KYMOS
437-29 LABORATORIOS RUBIÓ437-48 LIFE SCIENCE ENTREPRENEURS437-44 LYKERA BIOMED437-35 NANOTARGETING437-40 NEUROTEC PHARMA437-30 OMNIA MOLECULAR437-39 ORYZON GENOMICS437-24 PALAU PHARMA437-49 PALOBIOFARMA437-25 PLASMIA BIOTECH437-32 READYCELL437-43 RECERCA CLÍNICA437-46 REIG JOFRÉ GROUP437-26 SALVAT437-53 TRIFERMED437-27 VCN BIOSCIENCIES
COMPANIES
• ADVANCELL • BAKER & MCKENZIE• BIOEMPRÈN• BIOIBÉRICA• BIOKIT• CAIXA CAPITAL RISC
• ACC1Ó• BLOOD AND TISSUE BANK (BST)• BARCELONA CITY COUNCIL• BARCELONA SCIENCE PARK• BIOCAT• BIOMEDICAL ENGINEERING RESEARCH CENTRE (CREB-UPC)• BIONANOMED CATALUNYA NETWORK• BOSCH I GIMPERA FOUNDATION• CATALAN INSTITUTE OF NANOTECHNOLOGY (ICN) • CENTRE FOR GENOMIC REGULATION (CRG) • CLÍNIC FOUNDATION FOR BIOMEDICAL RESEARCH • GUTTMANN UNIVERSITARY INSTITUTE FOR NEUROREHABILITATION
• IMB-CNM NATIONAL MICROELECTRONICS CENTER (CSIC)• INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA (IQAC-CSIC)• IRB BARCELONA• LEITAT TECHNOLOGY CENTER• ONCOCAT NETWORK• PARC DE L'ALBA, ALBA SYNCHOTRON• POMPEU FABRA UNIVERSITY (UPF) • RESEARCH & TECHNOLOGY INSTITUTE FOR FOOD & AGRICULTURE (IRTA)• SECOT• UNIVERSITAT POLITÈCNICA DE CATALUNYA (UPC)• UNIVERSITAT POMPEU FABRA (UPF)
COMPANIES
INSTITUTIONS
BOOTH DISTRIBUTION
BIOCAT’S BOOTH
• DRACONIS PHARMA• ERA BIOTECH • ESTEVE• GESAWORLD • GRI-CEL• LACER
• NATURA BISSÉ INTERNATIONAL• PERFORMLAB • ROUSAUD COSTAS DURAN• SAGETIS BIOTECH• THROMBOTARGETS • YSIOS CAPITAL PARTNERS
AB-BIOTICS
Contact: Miquel A. [email protected] www.ab-biotics.com
AB-THERAPEUTICS
Contact: Carles Domènech [email protected] www.ab-therapeutics.com
ANAXOMICS
Contact: Vesna [email protected] www.anaxomics.com
AROMICS
Contact: Carmen Plasencia [email protected]
ARCHIVEL
Contact: Olga Rué [email protected] www.archivelfarma.com
BIONURE
Contact: Albert [email protected]
DRACONIS PHARMA
Contact: Lluis [email protected]
ERA BIOTECH
Contact: Miriam [email protected]
ESTEVE
Contact: Mark [email protected]
GP PHARM
Contact: Sandra Sá[email protected] www.gp-pharm.com
BCN PEPTIDES
Contact: Jordi Piró[email protected] www.bcnpeptides.com
BAKER&MCKENZIE
Contact: Montserrat [email protected]
ALTHIA
Contact: Anna [email protected]
BIOIBÉRICA
Contact: Josep Vergé[email protected]
BIOCHEMIZE
Contact: Jaume [email protected]
BIOEMPRÈN
Contact: Jaume [email protected]
CCOMPANIES
437-31 437-47 437-42
ADVANCELL
Contact: Clara Campàs de [email protected]
437-38 437-45 437-33
437-37 437-34
437-28
437-23
437
437
437 437
CAIXA CAPITAL RISK
Contact: Patricia Buré[email protected]
437
BIOKIT
Contact: Pau [email protected]
437 437
437 437
GESAWORLD
Contact: José María Pé[email protected]
437
HEXASCREEN CULTURETECHNOLOGIES
Contact: Javier Amayra [email protected] www.hexascreen.com
IMMUNOVATIVE DEVELOPMENTS
Contact: Natalia de la Figuera n�[email protected]
INTELLIGENT PHARMA
Contact: Ismael [email protected]
KYMOS
Contact: Joan Puig de [email protected] www.kymos.es
LABORATORIOS RUBIÓ
Contact: Ingrid Chasan [email protected] www.laboratoriosrubio.com
LACER
Contact: Xavier [email protected]
GRI-CEL
Contact: Dirk [email protected]
LYKERA BIOMED
Contact: Francesc Mitjans [email protected] www.lykerabiomed.com
GRIFOLS ENGINEERING
Contact: Oriol Argemí [email protected]
LIFE SCIENCE ENTREPRENEURS
Contact: François [email protected]
JANUS DEVELOPMENTS
Contact: Marion Chalumeau [email protected] www.janusdevelopments.com
NEUROTEC PHARMA
Contact: Marco Pugliese [email protected]
NANOTARGETING
Contact: Aurora Conill [email protected]
437-51 437-54 437-41
437-50 437-52 437-36 437-29
437-48 437-44 437-35
437-40
NATURA BISSE INTERNATIONAL
Contact: Joaquin Serra [email protected]
437
437
437
CCOMPANIES
ORYZON GENOMICS
Contact: Emili Torrell [email protected]
437-39
OMNIA MOLECULAR
Contact: Ralph Klingmann [email protected] www.omniamol.com
437-30
PROFILE OF DELEGATES
AB-BIOTIC
SAB-TH
ERAPEU
TICS
ADVANCELL
ALTHIA
ANAXOMICSAROMICS
ARCHIVELBAKER
&McKEN
ZIE
BCN PEPTID
ES
BIOCHEMIZE
BIOIBÉRICA
BIOEMPRÈN
BIOKITBIONURE CAIXA CAPITA
L RISK
DRACONIS PHARMA
ERA BIOTE
CHES
TEVE
GESAW
ORLDGP-PHARM GRI-C
ELGRIFO
LS EN
GINEE
RING
HEXASCREE
N CULTURE T
ECHNOLO
GIES
IMMUNOVATIV
E DEV
ELOPMEN
TS
INTE
LLIGEN
T PHARMA
JANUS DEV
ELOPMEN
TS
KYMOS LA
BORATORIOS RUBIÓ
SALVAT
LACER
LIFE S
CIENCE E
NTREP
RENEU
RS
LIKER
A BIOMED
NANOTARGET
ING
NATURA BISSE I
NTERNATIO
NAL
NEUROTE
C PHARMA
OMNIA MOLE
CULAR
ORYZON GEN
OMICS
PALAU PHARMA
PALOBIOFA
RMA
PERFORMLA
B
PLASMIA
BIOTECH
READYCEL
LREIG
JOFR
É GROUP
ROUSAUD COSTAS DURAN
SAGETIS BIOTE
CHTH
ROMBOTARGET
S
TRIFE
RMEDVCN BIOSCIEN
CES
YSIOS
01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
HUMAN HEALTH (DIAGNOSTIC - VACCINATIONS)
HUMAN HEALTH (THERAPEUTIC)
AGROFOOD (AGRICULTURE, LIVESTOCK FARMING, FOOD & FORESTRY)
ANIMAL HEALTH
COSMETICS
BIOPROCESSES, BIOFUELS, BIOMATERIALS
AUXILIARY SERVICES
ENVIRONEMENT
LABORATORY EQUIPMENT
BIOCATALYSIS
ACTIVE PHARMACEUTICAL INGREDIENTS
COMPUTATIONAL SERVICES
CONSULTANCY*
* (1) BUSINESS DEVELOPMENT (2) BIOPHARMACEUTICS ENGINEERING (3) TECHNOLOGY TRANSFER (4) PUBLIC HEALTH & HEALTH MANAGEMENT
LAW FIRM
VENTURE CAPITAL
DEVE
LOPM
ENT
PIPE
LIN
EAC
TIVI
TY
BASIC RESEARCH
PRECLINICAL (IN VITRO TRIAL)
PRECLINICAL (IN VIVO TRIAL)
CLINICAL PHASE I, II, & III
CLINICAL PHASE IV (IN MARKET)
PROD
UCT
STAT
UTS BASIC RESEARCH
PILOT PRODUCT
VALIDATION TRIALS
REQUEST FOR AUTHORISATION
IN MARKET
1 14 2 3
47 48 49 50
RECER
CA CLINICA
Some of the companies may fall into more than one category
COMPANIES' PROFILE
Apart from Biocat, there are other institutional representatives coming from universities, science & technology parks, research & technology centers, support entities, networks and public administration.
0%
43%
53%
57%
32%
17%
10% 20% 30% 40% 50% 60% 70%
BASIC RESEARCH
PRECLINICAL (IN VITRO TRIAL)
PRECLINICAL (IN VIVO TRIAL)
CLINICAL PHASE I, II, & III
CLINICAL PHASE IV (IN MARKET)
DEVELOPMENT PIPELINE
0% 5% 10% 15%
15%
17%
21%
6%
11%
20% 25%
BASIC RESEARCH
PILOT PRODUCT
VALIDATION TRIALS
REQUEST FOR AUTHORISATION
IN MARKET
PRODUCT STATUS
ACTIVITY
36,2%
72,3%
4,3%
0%
10%
20%
30%
40%
50%
60%
70%
80%
17%10,6% 8,5% 6,4%
10,6%12,8%
HUM
AN H
EALT
H(D
IAGN
OSTI
C-VA
CCIN
ATIO
NS)
HUM
AN H
EALT
H(T
HERA
PEUT
ICS)
AGRO
FOOD
ANIM
AL H
EALT
H
BIOP
ROCE
SSES
,BI
OFUE
LS, B
IOM
ATER
IALS
AUXI
LIAR
Y SE
RVIC
ES
OTHE
R
CON
SULT
ANCY
LAW
FIR
M/
VEN
TURE
CA
PITA
L
RECERCA CLINICA
Contact: Lluís [email protected]
YSIOS CAPITAL PARTNERS
Contact: Raúl [email protected]
TRIFERMED
Contact: Stephanie [email protected]
VCN BIOSCIENCIES
Contact: Manel Cascalló [email protected] www.vcnbiosciences.com
SAGETIS BIOTECH
Contact: Eduard [email protected]
PALAU PHARMA
Contact: Ignacio Faus [email protected] www.palaupharma.com
PALOBIOFARMA
Contact: Julio Castro [email protected] www.palobiofarma.com
REIG JOFRÉ GROUP
Contact: Ignacio Vila [email protected]
ROUSAUD COSTAS DURAN
Contact: Ignasi Costas [email protected]
READYCELL
Contact: Josep O. Nicolá[email protected]
PLASMIA BIOTECH
Contact: Esteve [email protected]
PERFORMALB
Contact: Marc [email protected]
SALVAT
Contact: Cristina [email protected] www.salvatbiotech.com
437-24
437
437-49 437-25
437-32 437-46
437-43 437-26 437-53
437-27
THROMBOTARGETS
Contact: Ignasi [email protected]
437
437 437
437
CCOMPANIES
INSTITUTE OFADVANCEDCHEMISTRYOF CATALONIA(IQAC-CSIC)
Contact: Isabel Masip [email protected]
BIOMEMS GROUPBIOSYSTEMS BIOENGINEERING(IMB-CNM, CSIC)
Contact: Francesc Xavier Muñ[email protected]
CLÍNIC FOUNDATIONFOR BIOMEDICALRESEARCH
Contact: Yolanda [email protected]
BIOCATContact: Adela Farré [email protected]
BOSCH I GIMPERAFOUNDATION
Contact: Inma Íñ[email protected]
BIOMEDICALENGINEERINGRESEARCH CENTRE(CREB-UPC)
Contact: Manel Gonzá[email protected]
UNIVERSITATPOLITÈCNICADE CATALUNYA (UPC)
Contact: Oscar [email protected]
LEITATTECHNOLOGICALCENTER
Contact: Francesc Mitjans [email protected] www.leitat.org
BARCELONACITY COUNCIL
Contact: Jordi Sacristan [email protected] www.bcn.cat/barcelonabusiness
ACC1Ó
Contact: Clara [email protected] www.acc10.com
BANC DE SANGI TEIXITS (BST)
Contact: Aurora Masip [email protected] www.bst.cat
UNIVERSITATPOMPEUFABRA (UPF)
Contact: Melquiades Calzado [email protected]
CENTRE FORGENOMICREGULATION (CRG)
Contact: Xavier Rubies [email protected]
BIONANOMEDCATALUNYA NETWORK
Contact: Carlos [email protected] www.bionanomedcat.org
IRB BARCELONA
Contact: Cristina Horcajada [email protected]
RESEARCH &TECHNOLOGYINSTITUTE FOR FOOD& AGRICULTURE (IRTA)
Contact: Eliecer Lopez [email protected]
GUTTMANNUNIVERSITARYINSTITUTE FORNEUROREHABILITATION
Contact: Josep M [email protected]
BARCELONASCIENCE PARK
Contact: Jesús Purroy [email protected]
437 437 437 437 437
437
437 437 437 437 437
437 437 437 437 437
437 437 437
CATALANINSTITUTEOF NANOTECHNOLOGY(ICN)
Contact: Jordi [email protected]
PARC DE L'ALBA,ALBA SYNCHOTRON
Contact: Guy Molé[email protected]
437
ONCOCAT NETWORK
Contact: Carlos [email protected]
437
IINSTITUTIONS
AGENDA
EVERY DAY:COMPANY
PRESENTATIONS
Ask us for thecomplete schedule!
7:30amCATALONIA RACE 5 KM.
Meeting point: Nine Zero Hotel Network in casual & healthy environment!
2:00pm – 2:45pmBREAKOUT SESSION
Room: 254A Crossing Borders and Boundaries – Emerging Strategies
to Promote International CollaborationCome learn new approaches from 4 leading
biotech regions: Massachusetts, North Carolina,Israel and Catalonia
3:30pm – 4:30pmCLUSTER HOUR: MEET EUROPE’S CLUSTERS
AND THEIR GLOBAL PARTNERSBioRegion of Catalonia presentation. Organiser: CEBR
Booth 3165 – European Commission
6:30pm – 7:30pmPRESENTATION OF CATALONIA INTERNATIONAL
LIFE SCIENCE REPORT – ERNST & YOUNG
7.30pm – 9.30pm CATALAN NETWORKING EVENT
Boston Common Hotel & Conference Center40 Trinity Place. Boston, MA 02116
TUESDAY,JUNE 19TH
SUNDAY,JUNE 17TH
1:00pm – 6:30pm
JUNE 20TH 3:00pm - ORYZON
International Cancer ClusterShowcase (satellite event)
Whitehead Institute.Nine Cambridge Center,Cambridge, MA 02142
INNOVATIVE ONCOLOGYPIPELINES PRESENTATION BY:
AB THERAPEUTICSONCOCAT NETWORKORYZON GENOMICS WEDNESDAY,
JUNE 20TH
Patriots Room - 104B
MORE INFOi
MORE INFOi
MORE INFOi
MORE INFOi
MORE INFOi
MORE INFOi
MORE INFOi
Venue: Boston Common Hotel - 40 Trinity Place, Boston, MA
WEDNESDAY, JUNE 20TH, 2012 7.30 pm - 9.30 pm
The event will count on the presence of R. Hon. Mr. Artur Mas,President of the Catalan Government
A Mediterranean cocktail and Catalan drinkswill be served during the network event
R.S.V.P.: [email protected]
Organized by: Golden Sponsor:
BOOTH 437
THE CATALAN DELEGATION INVITES YOU TO OUR
BIO 2012 RECEPTION
Anunci BESMARCH 11–13, 2013BARCELONA, SPAIN
www.ebdgroup.com/bes
WHERE THE GLOBAL BIOTECH INDUSTRY COMES TO PARTNER
7th Annual International Partnering Conference
Producer Supported by Regional Host Sponsors
Save the date and join us in Barcelona!
Why Barcelona?
Because it is the ideal location for your biobusiness.
Barcelona City Council and Biocat are proud to introduce you the “biocapital” of Southern Europe. With more than 480 companies, 430research groups on life sciences, 20science & technology parks, 10universities and 13 top level hospitals, Catalonia is the most dynamic bioregion in the Euro-Mediterranean area and its capital, Barcelona, the main biotechnology hub.
CONNECT, PARTNER & INNOVATE WITH
THE BIOREGIONOF CATALONIAAT BIO 2012
June 18-21, 2012 Booth 437
Boston Convention & Exhibition Center 415 Summer Street • Boston (USA)
More information at:
www.biocat.cat/bio2012
With the support of: